Alimera Sciences
Develops and commercialises ophthalmic medicines for patients with chronic retinal diseases
Highlights
- New on EvolcAdded 2026-10-30
About Alimera Sciences
Alimera Sciences develops and commercialises treatments for chronic retinal diseases. Its UK product portfolio includes ILUVIEN, a fluocinolone acetonide intravitreal implant.
The company works with patients, physicians, the medical community and patient organisations. It is focused on expanding its commercial reach and pursuing ophthalmic drug-delivery technologies and compounds through development, licensing or acquisition.
Alimera Sciences Limited was founded in 2012 and is headquartered in Hook, United Kingdom.
Product: Ophthalmic medicines for chronic retinal diseases, including the ILUVIEN intravitreal implant.
Jobs at Alimera Sciences
More biotech & pharma companies
Amphista Therapeutics
Develops Targeted Glue protein-degrader medicines for cancer, with a lead acute myeloid leukemia candidate in Phase 1New on EvolcAnanda Pharma
Develops cannabinoid-based medicines for inflammatory pain conditions and heart failureNew on EvolcAndrolabs
Men's health medicines, including testosterone replacement and erectile dysfunction therapies, for patients and healthcare professionalsNew on EvolcApis Assay Technologies
Molecular diagnostic assay kits and contract IVD development for diagnostics, biotech and pharma teamsNew on EvolcApollo Therapeutics
Portfolio biopharmaceutical company developing new medicines from university biomedical research and in-licensed clinical programsNew on EvolcApterna
Preclinical biotech developing liver-directed RNA therapies to restore liver function for patients with liver cancerNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- CookieFirst
- Google Universal Analytics
- Google reCAPTCHA
- WooCommerce
- WordPress
- jQuery
- nginx